Investor Presentaiton

BIOND BIOLOGICS ILT2: a multi-cell inhibitory immune checkpoint, on innate and adaptive immune cells An inhibitory immunomodulatory receptor (aka LILRB1, CD85j) Ig domains ITIMS ILT2 Receptor Expressed on multiple immune cell types: Lymphoid cells (T cells, NK cells), Myeloid cells (macrophages). Binds with the highest affinity to human leukocyte antigen (HLA)-G, a known immunosuppressive molecule expressed by multiple tumor types Generates inhibitory signals via ITIM-mediated recruitment of SHP- 1, resulting in potent inhibition of immune effector functions when bound by MHC ligands Extracellular lg-like domains bind to classical and non- classical MHC-I molecules ILT2, Ig-like transcript 2; IgSF, Immunoglobulin superfamily; ITIM, Intracellular tyrosine-based inhibitory motifs; SHP1, Src homology region 2 domain-containing phosphatase 1; MHC, Major histocompatibility complex; HLA, Human leukocyte antigen Biond Biologics Corporate Presentation | May 2021 | Non-confidential 9

View entire presentation